Filtrer vos résultats
- 2
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)2020, pp.S337-S338
Autre publication scientifique
hal-03551532v1
|
|||
|
Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective studyJournal of Crohn's and Colitis, 2020, 14 (1), pp.S547. ⟨10.1093/ecco-jcc/jjz203.793⟩
Article dans une revue
hal-03551537v1
|